Company name not found in the provided text. – FDA 483, Jun 30, 2011

This FDA Form 483 document details observations made during an inspection of a pharmaceutical manufacturing facility. The inspection identified four key deficiencies related to quality system and manufacturing controls.

Observation 1 notes the firm's failure to establish adequate procedures for the cleaning and maintenance of equipment. This indicates a potential risk to product quality and consistency due to improperly maintained machinery.

Observation 2 highlights that the firm did not adequately validate the manufacturing process for Drug X. This suggests a lack of documented evidence demonstrating that the process consistently produces a product meeting its predetermined specifications and quality attributes, which is a critical regulatory requirement.

Observation 3 states that the firm lacked proper controls to prevent contamination of Drug Y. This is a significant finding as it directly impacts product safety and purity, potentially leading to adverse health effects for consumers.

Finally, Observation 4 indicates that the firm did not maintain proper records of batch production and control. Accurate and complete batch records are essential for traceability, quality assurance, and demonstrating compliance with Good Manufacturing Practices (GMP). The absence of such records hinders the ability to investigate deviations, recall products, or verify product quality.

These observations collectively point to deficiencies in the facility's quality management system, process validation, contamination control, and documentation practices, all of which are critical for ensuring the safety, efficacy, and quality of manufactured drug products.